Developing non-traditional antibiotics promises novel strategies to combat multidrug-resistant organisms, but would they work? Are they feasible to develop?
Topics discussed:
- The notion of non-traditional antibiotics as potential therapeutics against MDR organisms.
- Increasing our understanding on the clinical efficacy of non-traditional antibiotics.
- Regulatory pathways for approval of such compounds.
Guest:
- Dr. John Rex, Chief Medical Officer, F2G Ltd. | Editor-in-Chief, AMR.solutions
Visit to browse issues and/or submit a manuscript.
Subscribe to Editors in Conversation (free) on , , , , via .